RESMED INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
The U.S. Court of Appeals for the Federal Circuit upheld a district court's dismissal of a patent lawsuit, ruling that the claims were directed to an abstract idea and lacked an inventive concept. The patent, owned by Craig L. Linden, was deemed ineligible for protection under 35 U.S.C. § 101. The case involved ResMed, Inc., which was sued for alleged patent infringement.
ETFs, led by FTCS, sold $198.0 million of ResMed (RMD) shares on Oct. 16, ending a four-day buying streak. FTCS exited its position entirely, while IHI and FTGS reduced holdings. RMD, a medical device company, reported $5.65B revenue (up 10.8% YoY) and a market cap of $33.7B. Its P/E is 22.98, P/B 5.25, and P/S 6.19.
On Friday, ETFs saw net outflows of $2.05 billion. SPY had inflows of $3.47 billion, while QQQ had outflows of $3.33 billion and IGV saw $746.5 million in outflows. Arch Capital Group (ACGL) had the highest additions at $185.2 million, and Gilead Sciences (GILD) had the highest trims at -$200.9 million.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning RMD (RESMED INC). Coverage has skewed bearish: 0 bullish, 1 neutral, and 2 bearish.
Recent RMD coverage spans financial news, earnings and regulation.
In the last 30 days, RMD insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($1.1M). The most active reporter was Farrell Michael J., Chairman and CEO, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
ResMed faces reduced legal exposure but may see short-term stock pressure as the case concludes.
Large ETF outflow likely pushes RMD lower in the short term.
ETF outflows may depress RMD price.
The insider sale may signal reduced confidence and could pressure the stock lower.
Analyst rating unchanged but price target raised modestly.
AlphAI scores every news story that mentions RMD with an AI model for sentiment and relevance, and aggregates insider trades from RESMED INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
The U.S. Court of Appeals for the Federal Circuit upheld a district court's dismissal of a patent lawsuit, ruling that the claims were directed to an abstract idea and lacked an inventive concept. The patent, owned by Craig L. Linden, was deemed ineligible for protection under 35 U.S.C. § 101. The case involved ResMed, Inc., which was sued for alleged patent infringement.
2 min readETFs, led by FTCS, sold $198.0 million of ResMed (RMD) shares on Oct. 16, ending a four-day buying streak. FTCS exited its position entirely, while IHI and FTGS reduced holdings. RMD, a medical device company, reported $5.65B revenue (up 10.8% YoY) and a market cap of $33.7B. Its P/E is 22.98, P/B 5.25, and P/S 6.19.
1 min readOn Friday, ETFs saw net outflows of $2.05 billion. SPY had inflows of $3.47 billion, while QQQ had outflows of $3.33 billion and IGV saw $746.5 million in outflows. Arch Capital Group (ACGL) had the highest additions at $185.2 million, and Gilead Sciences (GILD) had the highest trims at -$200.9 million.
1 min readFarrell Michael J. (Chairman and CEO) sold 4,991 shares of RESMED INC (RMD) at $226.33 ($1.13M total) on 2026-10-07 under a Rule 10b5-1 trading plan.
1 min readStifel maintained a Hold rating on ResMed (RMD) with a $235 price target, citing potential market share pressures. The firm expects RMD's U.S. device market share to decline to 75% if Philips reenters. RMD's Q4 earnings beat EPS estimates but missed on revenue. RBC and KeyBanc raised price targets, while Rothschild initiated with a Neutral rating.
2 min readResMed Inc. ($RMD) CEO Michael Farrell's 2026 compensation is estimated at $16.2M, up 9.43% from 2025. Insiders sold $RMD shares 7 times in 6 months. Hedge funds showed mixed activity, with some increasing and others decreasing their positions. Analysts have issued mixed price targets, with a median of $268.
1 min readResmed (RMD) will release its first-quarter fiscal 2027 earnings on October 29, 2026, after the NYSE close. A webcast will follow to discuss results and potential forward-looking information. The webcast and a replay will be available on the company's investor relations website.
1 min readASX healthcare stocks, led by CSL (ASX:CSL) and ResMed (ASX:RMD), gained institutional investor interest, with Morgan Stanley noting increased overweight positions. RBC Capital upgraded several healthcare stocks, citing better-than-expected earnings. Healius (ASX:HLS) plans to sell Agilex for $160M to Novotech, addressing balance sheet challenges. Paradigm Biopharmaceuticals (ASX:PAR) delayed its trading resumption to address financial matters.
5 min readResMed Inc. (RMD) reported a 9% revenue increase to $1.5B in Q4 2026, driven by strong demand for sleep devices. RBC Capital upgraded RMD to Outperform, raising its price target to $262. However, the company faces risks from competition, lower-than-expected 2027 guidance, and a ventilator recall. Hedge funds maintained interest, with some increasing stakes.
2 min readAnalysts rate ResMed (RMD) stock as 'Moderate Buy' with price targets up to $320, suggesting 40% upside from current levels, according to Barchart.
1 min read
